Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Fresenius Medical Care (NYSE:FMS) while raising the price target from $21 to $24.
May 15, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Fresenius Medical Care (NYSE:FMS) and raised the price target from $21 to $24.
The raised price target from $21 to $24 indicates a positive outlook from Truist Securities, which could lead to a short-term increase in FMS's stock price despite the Hold rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100